The Institutional Biosafety Committee (IBC) was established under the provisions of the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). The role of the IBC is to establish and implement policies that provide for the safe conduct of recombinant DNA research and to ensure compliance with the NIH Guidelines. In addition, the IBC oversees research involving infectious agents and toxic biological molecules. The IBC also reviews research protocols from grant applications submitted to extramural funding agencies to confirm that experiments will be conducted safely and in compliance with the NIH Guidelines.
The committee consists of members appointed by the Senior Vice President for Executive Affairs. Two members are not otherwise affiliated with the University, and represent the interests of the surrounding community with respect to health and protection of the environment.